inadvertently administering second dose of rabies pre-exposure prophylaxis series on day 6 instead of day 7 with no reported adverse event; off-label use as per local labelling due to using IMOVAX to finish rabies pre-exposure prophylaxis series after starting the first dose of the series with RabAvert with no reported adverse event; Initial information received on 05-Apr-2022 regarding an unsolicited valid non-serious case received via other health professional.  This case involves an unknown age and unknown gender patient who experienced inadvertently administering second dose of rabies pre-exposure prophylaxis series on day 6 instead of day 7 with no reported adverse event and off-label use as per local labelling due to using imovax to finish rabies pre-exposure prophylaxis series after starting the first dose of the series with rabavert with no reported adverse event while receiving vaccine IPV (VERO) (Imovax) and while treated with RABIES VACCINE INACT (CHICK EMBRYO) (Rabavert).  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect IPV (VERO) (dose, route, lot number and administration site: unknown) for Immunization.  On an unknown date, the patient started taking RABAVERT (RABIES VACCINE INACT (CHICK EMBRYO)) (dose, route and batch number: unknown) for pre-exposure prophylaxis rabies immunization.  It was reported that the first dose the patient received was RabAvert; states they ran out of RabAvert afterwards, and they were unable to order more so they ordered IMOVAX instead. Reportedly asks if it is okay if the patient finishes the rabies series using IMOVAX if their first dose was RabAvert. Reportedly asks to confirm that the IMOVAX pre-exposure prophylaxis series is 3 doses. It was reported that co-worker counted the days wrong, and they inadvertently administered the second dose of the pre-exposure prophylaxis series on day 6 instead of day 7 (inappropriate schedule of product administration) (event onset and latency: unknown). This situation is reported as a medication error due to inadvertently administering second dose of rabies pre-exposure prophylaxis series on day 6 instead of day 7. This situation is reported as an off-label use as per local labelling due to using IMOVAX to finish rabies pre-exposure prophylaxis series after starting the first dose of the series with RabAvert (off label use) (event onset and latency: unknown).  Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the events (inadvertently administering second dose of rabies pre-exposure prophylaxis series on day 6 instead of day 7 with no reported adverse event, off-label use as per local labelling due to using IMOVAX to finish rabies pre-exposure prophylaxis series after starting the first dose of the series with RabAvert with no reported adverse event).  At time of reporting, the outcome was Unknown for the event inadvertently administering second dose of rabies pre-exposure prophylaxis series on day 6 instead of day 7 with no reported adverse event and was Unknown for the event off-label use as per local labelling due to using imovax to finish rabies pre-exposure prophylaxis series after starting the first dose of the series with rabavert with no reported adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.